Galectin Therapeutics Overview
Latest ROE for Galectin Therapeutics: 20.16% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow20.16%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Galectin Therapeutics posts a ROE of 20.16%. That is below the Healthcare sector average of 29.33%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 29.33% is typical. Galectin Therapeutics's 20.16% is lower that level. That is roughly 31.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Galectin Therapeutics's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 20.16%; use YoY and peer views to separate noise from signal.
Context for GALT's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 29.33%), and (3) consistency with growth and profitability. This page covers the first two; Galectin Therapeutics's other metric pages and overview cover the third.
Judging Galectin Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 20.16% here, then scan peer and history charts to see if the gap is persistent.
